Articles tagged with Lymphoma
The Lymphoma Research Foundation has awarded grants of $300,000 and $200,000 to Drs. David Frank and Thomas Kipps for their research on Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). The grants aim to develop new treatments for patients with refractory disease.
A three-year study by University of Alberta researchers found that aerobic exercise training significantly improved physical functioning and overall quality of life in patients with lymphoma. The study showed a 46.4% complete response rate in the exercise group, compared to 30.8% in the usual care group.
Cold Spring Harbor Laboratory scientists uncover a large cache of genes that act as built-in barriers against cancer, including over 10 new tumor suppressor genes. The study reveals that even partial loss of function in these genes can accelerate tumor growth.
Researchers have discovered an experimental compound that selectively kills cancerous B lymphocytes while allowing normal B cells to survive. The study found that K252a disrupts a key signaling pathway involved in the growth of lymphoma cells, offering new hope for treating non-Hodgkin lymphoma.
Researchers found that adding high-dose cytarabine to methotrexate therapy improved complete remission rates (46%) and overall response rates (69%) in patients with primary central nervous system lymphoma. The combination also resulted in a lower risk of relapse and improved progression-free survival.
A new analysis reveals that adolescents and young adults with blood-related cancers have better long-term survival rates than those diagnosed in the 1980s. However, survival rates in this age group are still lower than those seen in younger children and some older adults.
Dr. Kai Fu receives $300K Clinical Investigator Career Development Award for mantle cell lymphoma research, focusing on miR-17~92 expression and its correlation with patient survival. The funding aims to support a pre-clinical study to determine the effectiveness of suppressing miR-17~92 in improving chemotherapy outcomes.
Researchers at UC Berkeley and TGen found a gene variant, rs6457327, associated with nearly twice the risk of developing follicular lymphoma, a cancer of the body's disease-fighting network. The presence of the G allele was protective against the disease, while the A allele increased risk.
Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke. After a median follow-up of almost 18 years, 96 patients developed cerebrovascular disease, with the incidence rate for stroke being 2.2 times that in the general population. Risk factors include radiation to the neck and mediastinum.
Researchers at Stanford University School of Medicine developed a machine that can analyze tiny blood samples for cancer-associated proteins, detecting subtle changes in protein modifications. The technique may provide a faster and less invasive way to track solid tumors and monitor treatment response.
A new study has found that maintenance rituximab therapy improves progression-free survival in patients with stage III-IV indolent lymphoma. The treatment showed significant benefits, including a 22% improvement in disease response and a 68% three-year progression-free survival rate.
Patients with relapsed follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than those without treatment. Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment.
Researchers find AID causes genetic malfunctions leading to Burkitt's lymphoma and potentially other cancers. The enzyme, responsible for immune system adaptation, also targets a cancer-promoting gene.
Researchers at USC have identified a key mechanism that occurs in the inception point of many human lymphomas, a process previously unknown. The study found that chromosomal translocations occur at CpG sites in early B-cells, driven by enzymes AID and RAG complex.
A study published by researchers at M.D. Anderson Cancer Center revealed that intense chemotherapy significantly reduces the risk of recurrence in young mantle cell lymphoma patients. In a median follow-up of seven years, 52% of patients aged 65 or younger achieved disease-free survival.
Mantle cell lymphoma cells rely on heat shock protein 90 to maintain their rapid growth. Researchers are using inhibitors to block this process, causing stress in the cells' machinery. The goal is to trigger apoptosis in cancer cells.
A new study reveals that poorer socioeconomic status increases mortality risk in non-Hodgkin lymphoma patients, while chemotherapy reduces the risk. Ethnic disparities are also observed, with African-Americans less likely to receive chemotherapy and living in poorer communities.
A research article compares CT findings in mesenteric tuberculosis and non-Hodgkin's lymphoma (NHL), revealing specific enhancement patterns and anatomic lymph node distribution. The 'sandwich sign' is more often found in NHL, aiding in differential diagnosis between tuberculosis and untreated NHL involving the small bowel mesentery.
Researchers found Rheb overexpression is sufficient to induce low-grade prostate neoplasias and contributes to lymphoma formation. Targeted inhibition of Rheb shows promise in counteracting tumor progression in both cancers.
A new study reveals that mantle cell lymphoma incidence is increasing, especially among men and Caucasians, with advanced stages detected in nearly 75% of patients. The research also highlights the need for better understanding of the disease's epidemiology and development of novel treatment agents.
Researchers at ESMO Conference Lugano report improved treatment outcomes for aggressive non-Hodgkin's lymphoma patients when chemotherapy is administered every 2 weeks, rather than every 3 weeks.
Researchers used PET scans to analyze 38 patients with non-Hodgkin's lymphoma treated with 90 ibritumomab tiuxetan. The study found that 89% of patients were in complete or partial remission after treatment, with a higher response rate for patients with limited cancer progression.
In a phase II clinical trial, 70% of patients with follicular lymphoma responded to treatment with galiximab and rituximab. The combination regimen achieved complete responses in 44% and partial responses in 26%. Further study is warranted to assess the efficacy and time-to-progression endpoint.
Researchers found that treatments for childhood Hodgkin's lymphoma increase the risk of dying from a second cancer or cardiovascular disease in adulthood. Women are especially vulnerable to breast cancer, while men are at risk of cardiovascular events.
A phase 1 clinical trial showed AME-133v had a potent tumor-halting response in patients with follicular lymphoma. The drug triggered signaling pathways within cells to slow or stop cancer growth, while causing minimal side effects.
A long-term study of twins has led USC researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein, interleukin-12. Lower levels of this protein may increase susceptibility to the disease.
Researchers at the University of Southern California found that combined positron emission tomography (PET) and computed tomography (CT) imaging yields greater accuracy when evaluating response to radiation therapy. This method helps identify complete responders and reduces the need for unnecessary chemotherapy treatments.
The study analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program and found that non-Hodgkin lymphoma patients showed significant improvements in five- and 10-year survival rates, with increases ranging from 26.8 to 27.1 percentage points across all age groups and tumor subtypes.
Researchers found that the antimalarial drug chloroquine effectively prevents cancer in mouse models of two human cancer syndromes, Burkitt lymphoma and ataxia telangiectasia. Chloroquine inhibited the development of Myc-induced lymphomas and ATM-deficient mice, but not p53-deficient mice.
Researchers have found that the Myc protein can stop the production of at least 13 microRNAs, which help control gene expression. Re-introducing repressed miRNAs into cancer cells suppressed tumor growth in mice, raising hopes for a novel therapy approach.
Researchers at the University of Texas M. D. Anderson Cancer Center report that a milder chemotherapy regimen before stem cell transplant resulted in complete remission for 45 of 47 patients with relapsed follicular lymphoma. Long-term follow-up showed improved overall survival and progression-free survival rates.
A new study has identified a direct link between Plasmodium falciparum antigens and Epstein-Barr virus (EBV) reactivation, increasing the risk of Burkitt lymphoma in children living in malaria-endemic areas. The researchers found that certain proteins from P. falciparum can spur latent EBV-infected cells into active production.
A University of Michigan study found that 86% of patients with follicular lymphoma survived after 8 years of treatment with Bexxar, a radioimmunotherapy drug. This success rate compares favorably to state-of-the-art chemotherapy regimens, making Bexxar an attractive option for patients.
Adding radioimmunotherapy to chemotherapy increased complete response rates for patients with follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma. Over 90% of study patients responded completely to the treatment, with limited side effects.
Alcohol drinking has been associated with a reduced risk of renal cell cancer. Childhood leukemia and lymphoma survivors face an elevated risk of secondary cancers, while treatment with clodronate did not improve survival for men with localized prostate cancer.
People infected with hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas, including non-Hodgkin's lymphoma and Waldenström's macroglobulinemia. The risk was found to be 20-30% higher for HCV-infected patients compared to uninfected patients.
A study found that hepatitis C virus (HCV) infection increases the risk of non-Hodgkin lymphoma by 20-30% and Waldenström macroglobulinemia by nearly three-fold. HCV is also linked to an increased risk of nonmalignant plasma cell disorders.
A study by radiologists at the University of Minnesota found that PET-CT detects muscular lymphoma more effectively than CT alone, revealing muscle involvement that may be overlooked. This breakthrough suggests that incorporating PET-CT into imaging protocols can lead to more accurate diagnoses and treatment plans.
Researchers discovered Nutlin-3a induces apoptosis in human PEL cell lines by disrupting LANA-p53 interaction, causing substantial tumor regression in mice with established PEL. This reactivation of the p53 pathway may provide a viable therapeutic option for individuals with KSHV-induced lymphomas.
Researchers at the University of Helsinki have discovered a new effective treatment modality for KSHV-infected lymphomas by reactivating the p53 pathway. The study shows that Nutlin-3a, a small-molecule inhibitor, selectively induces massive apoptosis in PEL cells.
International team develops standardized guidelines for assessing lymphoma treatment response, incorporating new imaging technologies. The revised guidelines aim to improve therapies and facilitate the development of new treatments.
A new study found that calcium supplements can reduce the risk of colorectal adenoma recurrence by up to 5 years after stopping supplementation. In contrast, antioxidant supplements did not show a significant effect on gastric cancer risk.
A recent study found that Hodgkin's lymphoma survivors who undergo lipid screening every five years live six months longer than those without screening. The study suggests that regular cholesterol screening is a cost-effective procedure to reduce the risk of heart disease in these patients.
Researchers found that doxycycline effectively regresses lymphoma in both positive and negative patients for Chlamydia psittaci, offering a safe alternative to chemotherapy and radiation. The study showed a 66% rate of disease-free survival among patients treated with doxycycline.
Radiation therapy significantly reduces risk of subsequent mastectomy and invasive breast cancer in both low- and high-risk patients with ductal carcinoma in situ (DCIS). Autoimmune conditions are also associated with increased risk of Hodgkin lymphoma, according to two new studies.
A new analysis of ACT trials found that UC patients in clinical remission had significantly higher rates of employment compared to those not in remission. Patients treated with REMICADE experienced a greater percentage of being employed at weeks 30 and 54, with 20.6% vs 8.3% for non-remitted patients.
Researchers found a substantial link between severe rheumatoid arthritis and increased risk of lymphoma. Patients with high RA activity experienced a 70-fold increase in lymphoma risk, while those with low activity had an 8-fold increase.
Researchers found combined therapy improved survival rates for patients with AIDS-related lymphoma, comparable to non-HIV patients with lymphoma treated with CHOP. For standard-risk ARL patients, 79% achieved complete remission and 50% survived after 47 months.
Researchers found that STAT1 expression was lower in SCCHN tumors than in normal tissue, and increasing STAT1 expression led to suppressed tumor growth. The study also suggests that STAT1 works as a tumor suppressor for SCCHN cells, but when its expression is lowered, SCCHN tumors grow.
Researchers have found a potential association between high blood levels of PCBs and furans with an increased risk of developing non-Hodgkin lymphoma. The study analyzed blood samples from 100 healthy volunteers and 100 non-Hodgkin lymphoma patients, revealing a link between three specific molecular forms of PCBs and cancer development.
ECCO 13 study investigates post-treatment parenthood success rates in Hodgkin's lymphoma patients, with radiotherapy and chemotherapy linked to higher pregnancy success. The research highlights the importance of preserving fertility in young cancer survivors.
Recent studies have shown that combining standard chemotherapy with new monoclonal antibody therapies can significantly improve survival rates for patients with follicular lymphoma. The latest study, led by Richard I. Fisher, found a 91% four-year survival rate for patients treated with this regimen.
Researchers studied 1,131 patients with early-stage Hodgkin's lymphoma and found that reducing the radiation dose from 30 Gy to 20 Gy significantly improved patient outcomes. Over 98% of patients experienced complete remission, while side effects were reduced.
Researchers found no link between breast-feeding and adult cancer risk, but high red meat consumption is associated with increased pancreatic cancer risk. A new vaccine approach may enhance tumor-specific immune response when combined with chemotherapy.
A model predicts that young women treated for Hodgkin lymphoma are at increased risk of developing breast cancer, with risks rising with age and radiation exposure. Current treatment guidelines may be reconsidered to minimize these risks.
Researchers found that viral protein vFLIP K13 actively promotes cancer cell growth through the NF-?B pathway, leading to increased lymphoma formation in transgenic mice. The study provides a promising new target for novel therapies against HHV8-associated tumors.
A Yale University study found that drinking alcohol may lower the risk of non-Hodgkin's lymphoma, particularly for Burkitt's lymphoma subtype. The study analyzed data from 15,175 individuals and found no significant association between age, sex, family history, or cigarette smoking with reduced risk.
Researchers are exploring a new approach to treating blood cancers by exploiting the natural process of programmed cell death, known as apoptosis. This could potentially kill tumour cells more effectively and improve treatment outcomes. The Leukemia and Lymphoma Society is providing strong support for this research.
Researchers have made advances in nuclear medicine, providing alternatives to traditional chemotherapy treatment for non-Hodgkin's lymphoma patients. The new treatments showed improved response rates and durations, exceeding those following chemotherapy, and offer a personalized dose option.
A pooled analysis of 15,000 individuals found that current drinkers had a 27% lower risk of non-Hodgkin's lymphoma compared to non-drinkers. The risk did not vary with alcohol consumption type or age of onset, but was lowest for Burkitt's lymphoma subtype.